These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18829182)

  • 1. [Activity of tigecycline against pathogen bacteria isolated in respiratory infectious disease in Europe. TEST study 2004-2007].
    Rio Y; Okamba P; Staal A; Didion J; Jurin F;
    Pathol Biol (Paris); 2009 Feb; 57(1):13-6. PubMed ID: 18829182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro activity of tigecycline on 760 bacterial strains isolated in the hospital university of Angers--2006-2009 TEST study].
    Bris C; Auger G; Kowalczyk F; Eveillard M; Joly-Guillou ML; Kempf M
    Pathol Biol (Paris); 2012 Dec; 60(6):336-9. PubMed ID: 22197193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):217-21. PubMed ID: 23522845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study.
    Silva-Sanchez J; Reyna-Flores F; Velazquez-Meza ME; Rojas-Moreno T; Benitez-Diaz A; Sanchez-Perez A;
    Diagn Microbiol Infect Dis; 2011 Jun; 70(2):270-3. PubMed ID: 21596226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tigecycline: CMI 50/90 towards 1766 Gram-negative bacilli (3rd generation cephalosporins resistant enterobacteriaceae), Acinetobacter baumannii and Bacteroides fragilis group, University Hospital - Montpellier, 2008-2011].
    Froment Gomis P; Jean-Pierre H; Rousseau-Didelot MN; Compan B; Michon AL; Godreuil S
    Pathol Biol (Paris); 2013 Dec; 61(6):282-5. PubMed ID: 23478078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
    Hoban DJ; Reinert RR; Bouchillon SK; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 May; 14():27. PubMed ID: 25958201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
    Farrell DJ; Flamm RK; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii.
    Garza-González E; Llaca-Díaz JM; Bosques-Padilla FJ; González GM
    Chemotherapy; 2010; 56(4):275-9. PubMed ID: 20693798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance.
    Draghi DC; Tench S; Dowzicky MJ; Sahm DF
    Chemotherapy; 2008; 54(2):91-100. PubMed ID: 18303257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H; Tan TY; Dowzicky MJ
    Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.